Cyclic peptide Fertiline

Phase 3Small molecule

AAssistance Publique - Hôpitaux de Paris

Cyclic peptide Fertiline is one of 7 small molecule programs targeting MPR. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MPRActive, not recruiting

MPRPhase 3

Active, not recruiting

Competition

Competitive Landscape

11 competitors in MPR

#DrugCompanyPhaseTrials

Lioresal

Novartis

Phase 3

1 2

Glycerin

CCalm Water Therapeutics LLC

Phase 3

1 3

Cyclic peptide Fertiline

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 4

Fragmin

Pfizer

Preclinical

1 5

Agenerase

GGlaxo Dba Glaxosmithkline

Preclinical

3 6

ECT-001-CB

EExCellThera inc.

Phase 2

1 7

Urine Collection

CCHU de Reims

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

MPR

NCT04954274

Clinical

Trials by Indication[1]

MPR1 trial

Improvement of Live Babies Rates After ICSI, Using cpFT

Active, not recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04954274·366 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cyclic peptide Fertiline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyclic peptide Fertiline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyclic peptide Fertiline. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Cyclic peptide Fertiline

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

MPR1 trial

References

Drug Info

Quick Facts

Related News